Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Meeting Abstract

    Zaman, K.; Modi, S.; Ohtan, S.; Lee, C.; Wang, Y.; Saxena, K.; Cameron, D. A.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 study
    Meeting Abstract

    Krop, I.; Manich, C. S.; Yamashita, T.; Park, Y. H.; Kim, S. B. K.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Clinical outcomes of proton craniospinal irradiation for patients with leptomeningeal carcinomatosis
    Meeting Abstract

    Wijetunga, N. A.; Mohammed, N.; Yamada, Y.; Wolden, S.; Seidman, A.; Yu, H.; Kris, M.; Malani, R.; Pentsova, E.; Boire, A.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Early trastuzumab interruption and recurrence-free survival in ERBB2-positive breast cancer
    Research Letter

    Copeland-Halperin, R. S.; Al-Sadawi, M.; Patil, S.; Liu, J. E.; Steingart, R. M.; Dang, C. T.; Yu, A. F.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
    Guidelines

    Cardoso, F.; Paluch-Shimon, S.; Senkus, E.; Curigliano, G.; Aapro, M. S.; AndreĢ, F.; Barrios, C. H.; Bergh, J.; Bhattacharyya, G. S.; Biganzoli, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Fractional SIR epidemiological models
    Journal Article

    Taghvaei, A.; Georgiou, T. T.; Norton, L.; Tannenbaum, A.
    Scientific Reports (2020)

    Fulltext@MSK | Save
  • Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer
    Journal Article

    Fernandez-Martinez, A.; Krop, I. E.; Hillman, D. W.; Polley, M. Y.; Parker, J. S.; Huebner, L.; Hoadley, K. A.; Shepherd, J.; Tolaney, S.; Lynn Henry, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors
    Guidelines

    Piccart, M. J.; Hilbers, F. S.; Bliss, J. M.; Caballero, C.; Frank, E. S.; Renault, P.; Kaoudjt, R. N.; Schumacher, E.; Spears, P. A.; Regan, M. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Circulating tumor DNA as a biomarker in oligometastatic non-small cell lung cancer
    Meeting Abstract

    Lebow, E. S.; Murciano-Goroff, Y.; Razavi, P.; Reis, J. S.; Flynn, J.; Zhang, Z.; Tu, H. Y.; Bertucci, C.; Lim, L. P.; Li, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save